Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2634)	4/20/2010 4:23:20 PM
From: Jibacoa	Respond to of 3722

NSPH is up for 4th day on a roll.<g> The stock was up 13.38% earlier and is still up 9.76% on volume of > 400Ks almost 4x its ADV. bigcharts.marketwatch.com NSPH received last month a notification from the FDA saying that its respiratory virus panel performance on the Verigene SP System has been categorized as "Moderate Complexity" under the CLIA Improvement Amendments of 1988. The "Moderate Complexity" designation allows the test to be run in more settings by a broader group of operators. The RVNATSP assay on the Verigene SP is the first NSPH test categorized as "Moderate Complexity" by the FDA. Before that, its products cleared by the FDA have been categorized as "High Complexity" and run on the original Verigene system. The company plans to file all of its previously cleared and future assays on the Verigene SP, which automates sample preparation, and should enable more tests to be categorized as "Moderate Complexity." <g> NSPH was also selected in March as one of the world's most innovative companies by MIT's Technology Review with its inclusion on the 2010 TR50 list, which identifies companies that demonstrate the most impressive and noteworthy innovations occurring in technology.<g> "Nanosphere is a leader in commercializing microfluidic technology for use in clinical diagnostic tests, helping to pave the way for personalized medicine. The FDA's recent approval of its instrument for pharmacogenomic testing is a significant milestone," said David Rotman, editor, Technology Review. Other companies chosen by MIT's Technology Review are AMZN, GSK, GOOG, Tesla Motors, and Twitter. NSPH is one of six public bio-medical companies listed. The other five public biomedical companies selected were ALNY, ATHN, GSK, ILMN, and MDT. The ACTAY is $6.88 but NSPH has now 3Qs of lower losses and triple digit improvements on revenues. It seems that with some good news the stock that is starting to get off from its Sep16 H at $8.24 could get to retest the Sep. H <g> bigcharts.marketwatch.com Bernard